CONTACT | Cancer biOengineered Novel microTissues unrAveling Cancer plasTicity

Summary
Triple Negative Breast Cancer is the most aggressive among breast cancer subtypes. The conventional neo-adjuvant therapy is ineffective in about 50% of cases, with patients presenting a higher risk of recurrence and metastasis. The failure of the currently available chemotherapeutic strategy is also due to the lack of cancer preclinical models that are “close-to-reality” and therefore able to accurately recapitulate the tumor microenvironment, the transcriptional reprogramming and the cancer cells plasticity of patients with poor outcomes. Currently, miRNAs and lncRNAs are believed to be key components in all major adaptation pathways and involved in the transcriptional reprogramming that occurs after TNBC treatment with neo-adjuvant therapy. Moreover, bioengineered preclinical in vitro models permit to study the molecular mechanisms underpinning adaptive responses to chemotherapy by selecting transcriptional phenotypes that somehow make tumor cells tolerant to drugs, without requiring a selection of genetic features.
The CONTACT project aims at developing a 3D bioengineered TNBC in vitro model able to shed light on the mechanisms of tumor cells reprogramming that trigger drug-tolerance. The model will include stromal components along with cancer cells and represent an important tool in studying the role of the stroma in transcriptional reprogramming. Bioengineered 3D breast cancer in vitro models will accelerate the establishment of personalized treatment protocols that take into account what exactly, in each patient, leads to transcriptional reprogramming. The CONTACT project will boost the scientific career of the experienced researcher and will lead her to an independent role in research. The project will also broad the expertise of the experienced researcher in the area of cancer genomics. Her expertise in 3D tumor models will pave the way for a new research line in the scientific portfolio of the host institution.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/893129
Start date: 15-01-2021
End date: 14-01-2023
Total budget - Public funding: 171 473,28 Euro - 171 473,00 Euro
Cordis data

Original description

Triple Negative Breast Cancer is the most aggressive among breast cancer subtypes. The conventional neo-adjuvant therapy is ineffective in about 50% of cases, with patients presenting a higher risk of recurrence and metastasis. The failure of the currently available chemotherapeutic strategy is also due to the lack of cancer preclinical models that are “close-to-reality” and therefore able to accurately recapitulate the tumor microenvironment, the transcriptional reprogramming and the cancer cells plasticity of patients with poor outcomes. Currently, miRNAs and lncRNAs are believed to be key components in all major adaptation pathways and involved in the transcriptional reprogramming that occurs after TNBC treatment with neo-adjuvant therapy. Moreover, bioengineered preclinical in vitro models permit to study the molecular mechanisms underpinning adaptive responses to chemotherapy by selecting transcriptional phenotypes that somehow make tumor cells tolerant to drugs, without requiring a selection of genetic features.
The CONTACT project aims at developing a 3D bioengineered TNBC in vitro model able to shed light on the mechanisms of tumor cells reprogramming that trigger drug-tolerance. The model will include stromal components along with cancer cells and represent an important tool in studying the role of the stroma in transcriptional reprogramming. Bioengineered 3D breast cancer in vitro models will accelerate the establishment of personalized treatment protocols that take into account what exactly, in each patient, leads to transcriptional reprogramming. The CONTACT project will boost the scientific career of the experienced researcher and will lead her to an independent role in research. The project will also broad the expertise of the experienced researcher in the area of cancer genomics. Her expertise in 3D tumor models will pave the way for a new research line in the scientific portfolio of the host institution.

Status

TERMINATED

Call topic

MSCA-IF-2019

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2019
MSCA-IF-2019